5-amino-1mq weight loss study Peptide Therapy 5-Amino-1MQ - the Enzyme That

Phase 2 clinical trial data published in the New England Journal of Medicine (Jastreboff et al., 2023) demonstrated mean body weight reductions of up to approximately 24% over 48 weeks in adults with obesity a notable finding, though long-term durability data and head-to-head comparisons with other treatments are not yet available

It works by blocking NNMT, which boosts NAD+ levels and improves the bodys ability to burn stored fat

Enhanced NAD+ levels may support improved mitochondrial efficiency, cellular energy production, and metabolic pathways related to fat utilization and vitality

It reduces the potential gastrointestinal side effects